Pharmaceutical UK-headquartered specialty drugmaker Advanz Pharma today announced that its board of directors has reached an agreement on the terms of a cash offer, to be made by a subsidiary (“Bidco”) of Nordic Capital, under which Nordic Capital will acquire the entire issued and to-be-issued limited voting share capital of Advanz, in a deal worth about $846 million. 27 January 2021